Resverlogix
Late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses.
Launch date
Employees
Market cap
$12.2m
Enterprise valuation
$21m (Public information from Sep 2024)
Share price
CAD0.07 RVX.TO
Calgary Alberta (HQ)
Authorizing premium user...